Assay News and Research

RSS

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

The PAM50 breast cancer signature developed at the University of Utah and Huntsman Cancer Institute received FDA approval and will launch at ARUP Laboratories in Salt Lake City. The test utilizes gene expression data from 50 genes weighted together with clinical variables to generate a risk category and numerical score to assess a patient's risk of distant recurrence at ten years in postmenopausal women with node-negative (Stage I or II) or node-positive (Stage II), Hormone Receptor-Positive (HR+) breast cancer.

16 Dec 2013

NTU researchers find way to block invasion of Malaria parasite in blood cells

Scientists from Singapore's Nanyang Technological University have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.

16 Dec 2013

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.

13 Dec 2013

WHO hands over management of world's largest public collection of TB strains to ITM in Antwerp

The World Health Organisation handed over the management of the world's largest public collection of tuberculosis strains to the Institute of Tropical Medicine in Antwerp. These TB-strains play a key role in supporting scientific research into infectious diseases, particularly towards a better understanding of the TB bacterium's drug resistance.

13 Dec 2013

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

For my MD thesis I modified and evaluated an immunological assay that detected the cell death products “nucleosomes” as a new blood-based cancer biomarker. As cell death processes are enhanced or suppressed during different stages of tumor development, it was assumed that they may enable stage-dependent detection of cancer disease.

12 Dec 2013

New assay allows rapid and sensitive detection of Chlamydia trachomatis

Researchers have developed a new assay for rapid and sensitive detection of Chlamydia trachomatis, the most common sexually transmitted infection (STI) in humans.

12 Dec 2013

New Journal presents techniques for finding new uses for approved drugs

Mary Ann Liebert, Inc., publishers is pleased to announce Drug Repurposing, Rescue, and Repositioning, a dynamic new peer-reviewed journal that will present techniques and tools for finding new uses for approved drugs—particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

12 Dec 2013

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014.

From NanoString Technologies 11 Dec 2013

Scientists target protein-detection approach to systematically measure human repertoire of proteins

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

9 Dec 2013

Biocartis, VIB partner to develop novel MSI biomarkers for colorectal cancer

Today Biocartis and VIB announced their exclusive license agreement on a novel panel of microsatellite instability biomarkers for several cancers, in particular colorectal cancer.

6 Dec 2013

New method for counting tumor-fighting cells to predict ovarian cancer

One way to predict survival of many types of cancer is by counting the number of tumor-attacking immune cells that have migrated into the tumor in an effort to eradicate it - a sign of the body's immune response to the cancer. However, quantifying these armies of immune cells has been difficult - until now.

5 Dec 2013

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

Finnish healthcare company Biohit Oyj and American company Dynex Technologies, Inc. have signed an agreement for the distribution of the two-microplate DS2®, four-microplate DSX® and 12-microplate Agility® automated ELISA (enzyme-linked immunosorbent assay) processing systems, for use with the Biohit Oyj GastroPanel.

4 Dec 2013

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today releases new data showing that when combining two of its proprietary NuQ assays into one test, they can achieve 85% detection rates at 85% specificity for colorectal cancer. The data also shows that Volition’s two-assay test can detect more than 50% of precancerous polyps. These new findings come from its ongoing prospective study with CHU Dinant Godinne | UCL Namur Hospital in Belgium.

4 Dec 2013

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

NanoLogix, Inc. an innovator in the rapid detection, identification of live bacteria, and determination of their antibiotic resistance and sensitivity, announces that they are working with Nasaem-Aljazira, a Saudi Arabian company headquartered in Riyadh, to establish exclusive distribution and/or manufacturing of NanoLogix products in Saudi Arabia and the Arabian Gulf region, also known as the Gulf Cooperation Council (GCC) area.

4 Dec 2013

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

PrimeraDx, a molecular diagnostics company, announced today that the ICEPlex C. difficile Assay Kit and the ICEPlex System have received 510(k) clearance from the United States Food and Drug Administration.

3 Dec 2013

Xagenic announces closing of $20 million Series B financing

Xagenic Inc., a molecular diagnostics company developing the first lab-free molecular diagnostic platform with a 20 minute time-to-result, today announced the close of a Series B financing totaling $20 million. The round was led by new investor Domain Associates, LLC, which was joined by existing investors including CTI Life Sciences Fund and the Ontario Emerging Technologies Fund.

2 Dec 2013

New biomarkers to improve diagnostics of prostate cancer

New biomarkers will improve diagnostics of endemic diseases in future, such as prostate cancer. Their mission: to recognize the tumor earlier and classify it more precisely - thereby helping avoid unnecessary operations.

2 Dec 2013

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has produced a free whitepaper titled ‘The importance of enrichment assay choice and optimisation for confident variant detection.’ The paper investigates the main strategies employed to optimise target enrichment for next generation sequencing assays, assisting researchers to make informed decisions when designing studies.

From Oxford Gene Technology 30 Nov 2013

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

People inherit different versions of any particular gene, and some genes affect how patients process and metabolize medicines. This especially holds true for people with cardiovascular (CV) disease. They may be fast, slow or non-metabolizers and might also react badly (with serious adverse events) to certain drug therapies or not at all.

27 Nov 2013

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

New methods for the laboratory-scale synthesis of coumarin-based drugs were developed in a recent study completed at the University of Eastern Finland. In his doctoral thesis, Lic. Phil. Juri Timonen also developed new analytical methods for the fast identification of natural and non-natural coumarins.

26 Nov 2013

Assay News and Research

PAM50 FDA-cleared breast cancer test to be launched at ARUP Laboratories

NTU researchers find way to block invasion of Malaria parasite in blood cells

Study shows effectiveness of PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay

WHO hands over management of world's largest public collection of TB strains to ITM in Antwerp

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

New assay allows rapid and sensitive detection of Chlamydia trachomatis

New Journal presents techniques for finding new uses for approved drugs

Nanostring Technologies announces nationwide availability of Prosigna Breast Cancer Assay in 2014

Scientists target protein-detection approach to systematically measure human repertoire of proteins

Biocartis, VIB partner to develop novel MSI biomarkers for colorectal cancer

New method for counting tumor-fighting cells to predict ovarian cancer

Biohit Oyj to distribute Dynex automated ELISA systems with Gastropanel

VolitionRx's two-assay test can detect 85% of colorectal cancer, more than 50% of precancerous polyps

Nanologix collaborates with Saudi company to distribute Nanologix products in Arabian Gulf region

PrimeraDx gets FDA clearance for ICEPlex C. difficile Assay Kit and ICEPlex System

Xagenic announces closing of $20 million Series B financing

New biomarkers to improve diagnostics of prostate cancer

New whitepaper examines main strategies employed to optimise target enrichment for NGS assays

Genetics and cardiovascular drugs: an interview with Nancy Lurker, CEO of PDI and Paul Kinnon, CEO of Transgenomic, Inc.

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News